Peptides News and Research

RSS

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8.

2 Jun 2010

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Nephrologists must consider fluid overload effects when prescribing dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology. The fluid overload biomarker, N-terminal pro-brain-type natriuretic peptide, previously known as a "cardiac biomarker" in dialysis patients, is an important component of managing patients with kidney disease.

28 May 2010

Important milestone in development of ORMD-0801 published in DOM journal

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.

26 May 2010

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

The Alzheimer's Drug Discovery Foundation announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

25 May 2010

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Agilent Technologies Inc. today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

25 May 2010

New England Peptide launches NEPTune line of custom proteomics reagents

New England Peptide (NEP) today introduced NEPTune TM, a new proprietary line of custom proteomics reagents to help its customers to quickly and inexpensively maximize biomarker assay development and produce consistent results.

21 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

Research and movement in future towards universal influenza virus vaccine

Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their findings today in the inaugural issue of mBio-, the first online, open-access journal published by the American Society for Microbiology.

20 May 2010

Basque researchers find new Alzheimer's-related mechanism

Researchers from the University of the Basque Country have found a new Alzheimer's-related mechanism that could give rise to the development of new therapies against this disease. The study was recently published in the Cell Calcium journal, and the authors have already applied for a European patent to protect the commercial exploitation of this new discovery.

20 May 2010

MicroStockProfit.com releases investment report on Discovery Laboratories

MicroStockProfit.com announces an investment report featuring Discovery Laboratories Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

20 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

2010 funding program for Inova Life Sciences - George Mason University research collaboration open

What do you get when you mix a world-class health system with an innovative, entrepreneurial university? A very successful research collaboration.

20 May 2010

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Discovery Laboratories, Inc. announces today that the revalidation of its optimized fetal rabbit Biological Activity Test (BAT, an important quality control release and stability test) has been completed, having met all pre-specified acceptance criteria.

19 May 2010

Research findings help explain diverse genetic susceptibility for alcohol use disorders

A genetic variant of a receptor in the brain's reward circuitry plays an important role in determining whether the neurotransmitter dopamine is released in the brain following alcohol intake, according to a study led by researchers at the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health. Dopamine is involved in transmitting the euphoria and other positive subjective effects produced by alcohol.

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced the pricing of its previously announced underwritten public offering of 11,500,000 units of its securities at a public offering price of $0.41 per unit.

19 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies, Inc. today announced its financial results for the first quarter 2010.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Peptides News and Research

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Important milestone in development of ORMD-0801 published in DOM journal

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

New England Peptide launches NEPTune line of custom proteomics reagents

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Research and movement in future towards universal influenza virus vaccine

Basque researchers find new Alzheimer's-related mechanism

MicroStockProfit.com releases investment report on Discovery Laboratories

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

2010 funding program for Inova Life Sciences - George Mason University research collaboration open

Discovery Labs revalidates optimized BAT in program to gain FDA approval of Surfaxin for RDS

Research findings help explain diverse genetic susceptibility for alcohol use disorders

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

Emisphere Technologies first-quarter net loss increases to $18.5 million

Soligenix first-quarter revenues decrease to $336,000

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News